Sintx Technologies Announces Board Chairman Transition
Leadership Change at Sintx Technologies: Dr. Sonny Bal has retired as Chairman of the Board, with Eric Olson, the current CEO, appointed as the new Chairman, effective immediately. Dr. Bal will remain on the Board to support the company's strategic objectives.
Focus on Growth and Innovation: Under Olson's leadership, Sintx is prioritizing high-growth opportunities in biomedical applications, aiming to enhance commercialization efforts and explore strategic partnerships, licensing, and M&A initiatives.
Trade with 70% Backtested Accuracy
Analyst Views on SINT
About SINT
About the author
SINTX Appoints New President to Accelerate Revenue Growth
- Leadership Change: SINTX Technologies has appointed Ryan Elmore as the new President, effective March 16, 2026, bringing over 15 years of experience in advanced biomaterials and medical device commercialization, which is expected to facilitate the company's transition from a product-focused entity to a broader biomaterials platform company.
- Commercialization Strategy: Elmore will be responsible for executing SINTX's business and operational strategy, particularly in advancing the commercialization of SiNERGY™ silicon nitride technologies across new product categories such as sutures, mesh, and wound dressings, which is anticipated to significantly enhance the company's market share and revenue potential.
- Technology Expansion: SINTX is expanding its capabilities to support the development of multiple material forms, including 3D-printable filaments, extruded rods, and sheet stock, aimed at simplifying the evaluation and adoption processes for contract manufacturers and strategic partners, thereby accelerating market entry for new products.
- Market Opportunities: The company believes that its proprietary silicon nitride technology and expanding intellectual property portfolio will enable multiple commercial pathways across both implantable and non-implantable medical applications, further strengthening its competitive position in the biomaterials sector.
SINTX Technologies to Present at Sidoti Year End Virtual Investor Conference
- Investor Conference: SINTX Technologies will present at Sidoti's Year End Virtual Investor Conference on December 10-11, 2025, which is expected to attract significant investor attention and enhance the company's visibility in the capital markets.
- Presentation Timing: The management team is scheduled to speak on December 10, 2025, at 3:15 PM ET, aiming to showcase their advanced silicon nitride biomaterials technology, potentially piquing the interest of prospective investors.
- One-on-One Meeting Arrangements: Investors can schedule one-on-one meetings with SINTX's management via email, facilitating deeper engagement and understanding of the company's business and technology, which may influence investment decisions.
- Company Background: Headquartered in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company focused on developing and commercializing silicon nitride biomaterials for medical and other high-value applications, demonstrating its innovative capabilities in the high-tech sector.
SINTX Technologies to Present at Sidoti's Year End Virtual Investor Conference
- Investor Conference Appearance: SINTX Technologies will present at Sidoti's Year End Virtual Investor Conference on December 10-11, 2025, which is expected to attract significant investor attention and enhance the company's visibility in the capital markets.
- Presentation Schedule: The management team is scheduled to speak on December 10, 2025, at 3:15 PM ET, aiming to showcase their advanced silicon nitride biomaterials and related technologies, thereby increasing market awareness of their products.
- One-on-One Meeting Opportunities: Investors can schedule one-on-one meetings with SINTX's management via email, which not only helps deepen investor understanding of the company but may also facilitate potential investment opportunities.
- Company Background: Headquartered in Salt Lake City, Utah, SINTX Technologies focuses on developing and commercializing silicon nitride biomaterials for high-value applications, demonstrating its technological strength and market potential in the medical field.
SINTX Technologies Obtains FDA Approval for SINAPTIC® Foot and Ankle Implant System
FDA Clearance: SINTX Technologies received FDA 510(k) clearance for its SINAPTIC® Foot & Ankle Osteotomy Wedge System, allowing the company to enter the U.S. reconstructive foot and ankle surgery market, with a commercial launch planned for Q1 2026.
Innovative Biomaterial: The SINAPTIC system utilizes SINTX's proprietary silicon nitride, which offers advantages such as superior osteointegration, bacteriostatic properties, and enhanced imaging visibility, positioning it as a competitive alternative to traditional metal implants in orthopedic procedures.
Reasons to Consider SINTX TECHNOLOGIES, INC. (SINT) as a Strong Momentum Stock: Is It Time to Buy?
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation of selling them at even higher prices. The Zacks Momentum Style Score helps investors identify stocks with strong momentum, such as SINTX TECHNOLOGIES, INC., which currently holds a score of B and a Zacks Rank of #2 (Buy).
SINTX Technologies Performance: SINTX has shown significant price increases, with a 5.08% rise over the past week and a 56.36% increase over the last quarter, outperforming the S&P 500. Additionally, recent earnings estimate revisions have been positive, contributing to its favorable momentum score.
Ascendiant Capital Reaffirms Buy Rating on SINTX Technologies, Adjusts Price Target to $25
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Community: Joining Benzinga Pro connects traders with over 10,000 serious investors and provides access to exclusive stories and insights from Benzinga reporters.
SINTX Appoints New President to Accelerate Revenue Growth
- Leadership Change: SINTX Technologies has appointed Ryan Elmore as the new President, effective March 16, 2026, bringing over 15 years of experience in advanced biomaterials and medical device commercialization, which is expected to facilitate the company's transition from a product-focused entity to a broader biomaterials platform company.
- Commercialization Strategy: Elmore will be responsible for executing SINTX's business and operational strategy, particularly in advancing the commercialization of SiNERGY™ silicon nitride technologies across new product categories such as sutures, mesh, and wound dressings, which is anticipated to significantly enhance the company's market share and revenue potential.
- Technology Expansion: SINTX is expanding its capabilities to support the development of multiple material forms, including 3D-printable filaments, extruded rods, and sheet stock, aimed at simplifying the evaluation and adoption processes for contract manufacturers and strategic partners, thereby accelerating market entry for new products.
- Market Opportunities: The company believes that its proprietary silicon nitride technology and expanding intellectual property portfolio will enable multiple commercial pathways across both implantable and non-implantable medical applications, further strengthening its competitive position in the biomaterials sector.
SINTX Technologies to Present at Sidoti Year End Virtual Investor Conference
- Investor Conference: SINTX Technologies will present at Sidoti's Year End Virtual Investor Conference on December 10-11, 2025, which is expected to attract significant investor attention and enhance the company's visibility in the capital markets.
- Presentation Timing: The management team is scheduled to speak on December 10, 2025, at 3:15 PM ET, aiming to showcase their advanced silicon nitride biomaterials technology, potentially piquing the interest of prospective investors.
- One-on-One Meeting Arrangements: Investors can schedule one-on-one meetings with SINTX's management via email, facilitating deeper engagement and understanding of the company's business and technology, which may influence investment decisions.
- Company Background: Headquartered in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company focused on developing and commercializing silicon nitride biomaterials for medical and other high-value applications, demonstrating its innovative capabilities in the high-tech sector.
SINTX Technologies to Present at Sidoti's Year End Virtual Investor Conference
- Investor Conference Appearance: SINTX Technologies will present at Sidoti's Year End Virtual Investor Conference on December 10-11, 2025, which is expected to attract significant investor attention and enhance the company's visibility in the capital markets.
- Presentation Schedule: The management team is scheduled to speak on December 10, 2025, at 3:15 PM ET, aiming to showcase their advanced silicon nitride biomaterials and related technologies, thereby increasing market awareness of their products.
- One-on-One Meeting Opportunities: Investors can schedule one-on-one meetings with SINTX's management via email, which not only helps deepen investor understanding of the company but may also facilitate potential investment opportunities.
- Company Background: Headquartered in Salt Lake City, Utah, SINTX Technologies focuses on developing and commercializing silicon nitride biomaterials for high-value applications, demonstrating its technological strength and market potential in the medical field.
SINTX Technologies Obtains FDA Approval for SINAPTIC® Foot and Ankle Implant System
FDA Clearance: SINTX Technologies received FDA 510(k) clearance for its SINAPTIC® Foot & Ankle Osteotomy Wedge System, allowing the company to enter the U.S. reconstructive foot and ankle surgery market, with a commercial launch planned for Q1 2026.
Innovative Biomaterial: The SINAPTIC system utilizes SINTX's proprietary silicon nitride, which offers advantages such as superior osteointegration, bacteriostatic properties, and enhanced imaging visibility, positioning it as a competitive alternative to traditional metal implants in orthopedic procedures.
Reasons to Consider SINTX TECHNOLOGIES, INC. (SINT) as a Strong Momentum Stock: Is It Time to Buy?
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation of selling them at even higher prices. The Zacks Momentum Style Score helps investors identify stocks with strong momentum, such as SINTX TECHNOLOGIES, INC., which currently holds a score of B and a Zacks Rank of #2 (Buy).
SINTX Technologies Performance: SINTX has shown significant price increases, with a 5.08% rise over the past week and a 56.36% increase over the last quarter, outperforming the S&P 500. Additionally, recent earnings estimate revisions have been positive, contributing to its favorable momentum score.
Ascendiant Capital Reaffirms Buy Rating on SINTX Technologies, Adjusts Price Target to $25
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Community: Joining Benzinga Pro connects traders with over 10,000 serious investors and provides access to exclusive stories and insights from Benzinga reporters.
